Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET)  by Duhaylongsod, Francis G. et al.
DETECTION OF PRIMARY 
AND RECURRENT LUNG 
CANCER BY MEANS OF F-18 
FLUORODEOXYGLUCOSE 
POSITRON EMISSION 
TOMOGRAPHY (FDG PET) 
Positron emission tomography (PET), with the glucose analog F-18 fluoro- 
deoxyglucose (FDG), takes advantage of the enhanced glucose uptake 
observed in neoplastic ells. We examined whether the detection of prefer- 
ential FDG uptake with PET permits differentiation between benign and 
malignant focal pulmonary lesions in patients with suspected primary or 
recurrent lung cancer. Between November 1991 and September 1993, 100 
patients with indeterminate focal pulmonary abnormalities including 16 
patients who had previous lung resections for cancer were prospectively 
studied. Tissue diagnosis was obtained by transbronchial or percutaneous 
biopsy (n = 49) and open biopsy or resection (n = 35). Three patients 
underwent extended observation (>2 years) alone. Excluded were 13 
patients lacking firm pathologic diagnoses and less than 2-year follow-up. 
FDG activity in the lesion was expressed as a calculated standardized 
uptake ratio. Mean standardized uptake ratio ( -  standard eviation) was 
6.6 (-+3.1) in 59 patients with cancer versus 2.0 (-+1.6) in 28 with benign 
disease (p = 0.0001; unpaired t test, two-sided). With a standardized uptake 
ratio >_2.5 used for detecting malignancy, sensitivity, specificity, and accuracy 
were 97% (57/59), 82% (23/28), and 92% (80/87), respectively. Notably, in 
patients evaluated for pulmonary abnormalities after lung resection for 
cancer, all chest recurrences were correctly identified. The exceptional 
sensitivity of FDG PET demonstrates that malignant pulmonary lesions 
preferentially accumulate FDG, which results in a standardized uptake 
ratio _>2.5. PET may be useful for distinguishing recurrent tumor from 
postoperative, or postradiation, changes. If performed in all patients before 
open biopsy, PET increases the diagnostic yield by reducing the number of 
patients who have benign lesions at operation. Moreover, by lowering 
expenditures fo r  hospitalization and other diagnostic procedures, FDG 
PET may significantly reduce health care costs. (J THORAC CARDIOVASC 
SURG 1995;110:130-40) 
Francis G. Duhaylongsod, MD, a Val J. Lowe, MD, b 
Edward F. Patz, Jr., MD, b Anna L. Vaughn, RN, a 
R. Edward Coleman, MD, b and Walter G. Wolfe, MD, a Durham, N.C. 
F ocal pulmonary abnormalities frequently present a diagnostic hallenge. In particular, radiographic 
lesions that arise in the setting of preexisting lung 
disease or treatment-induced soft tissue changes 
often require invasive biopsy for diagnosisl Because 
the risk of complications and death resulting from 
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surgery may be substantial in certain high-risk pa- 
tients, less invasive chest imaging techniques are 
commonly used. Unfortunately, chest radiography 
and computed tomography (CT) have varying sen- 
sitivities ranging from 52% to 80% and lack suffi- 
cient specificity to provide a definitive diagnosis. 1,2 
Consequently, increasing interest has focused on 
imaging techniques that rely on metabolic rather 
than anatomic properties of lung cancer as a means 
to guide medical therapy. One example is positron 
emission tomography (PET). 
PET, using the glucose analog fluorine-18-fluoro- 
deoxyglucose (FDG), takes advantage of the en- 
hanced glucose uptake observed in neoplastic ells. 
First appreciated by Warburg, Wind, and Negleis 3in 
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Fig. 1. SURs for benign and malignant pulmonary abnormalities9 Group means depicted by horizontal 
bars. SUR threshold for malignancy denoted by dashed line. 
1923, the increased activity of key glycolytic enzymes 
in malignant umor cells has since been verified by 
others. 4 Entering the cell through facilitated trans- 
port, FDG is phosphorylated by hexokinase and 
trapped intracellularly. Because FDG-6-phosphate 
is metabolized slowly, its rate of appearance within 
the cell correlates directly with glycolytic flux. 4 PET 
quantitates FDG activity in vivo and identifies those 
lesions with increased glycolytic activity suggestive 
of malignancy. 
This study examined the diagnostic accuracy of 
FDG PET in differentiating between benign and 
malignant focal pulmonary lesions in patients with 
indeterminate pulmonary abnormalities after chest 
radiography and CT, as well as suspected primary or 
recurrent lung cancer. On the basis of the results 
from this study, a rational strategy incorporating 
PET imaging in the work-up of indeterminate pul- 
monary abnormalities i  suggested, with special em- 
phasis placed on detecting recurrent cancer after 
previous lung resection and irradiation. Finally, 
because of the financial expense associated with 
PET imaging, issues regarding health care costs are 
also addressed. 
Patients and methods 
Between November 1991 and September 1993, patients 
referred to the Duke University Medical Center chest 
medicine and thoracic surgery clinics with indeterminate 
focal pulmonary abnormalities by chest radiography and 
CT were eligible for enrollment into the study. Protocol 
design was approved by the institutional review board, and 
informed consent was obtained in all participants. Rea- 
sonsfor study exclusion included age less than 18 years, 
pregnancy, scheduling constraints resulting from immedi- 
acy of operation, and patient refusal. 
All patients fasted for 4 hours before the study. The 
patients were positioned in the PET unit so that the 
pulmonary lesions were near the center of the longitudinal 
field of view. The PET unit j(4096 Plus; General Electric 
Medical Systems, Milwaukee, Wis.) comprised eight de- 
tector ings positioned in a cylindric array9 This produced 
15 axial images along a 97 mm longitudinal field with a 
spatial resolution of about 5 mm. Image processing and 
reconstruction were performed with a VAX 4000-300 
computer system and a VAX 3100 workstation (Digital 
Equipment, Marlboro, Mass.). After January 1993, a 
second PET unit was added (Advance; General Electric 
Medical Systems) containing 18 detector ings and pro- 
ducing 35 axial images along a 150 mm longitudinal field; 
image processing and reconstruction were performed with 
a Hewlett-Packard Apollo Series 765 (Hewlett-Packard 
Company, Andover, Mass9149 Transmission scans were 
performed with germanium 68 pin sources to correct for 
soft tissue attenuation and to facilitate localizing the 
radiographic abnormality. Emission images were obtained 
over a 20-minute period starting 30 minutes after intrave- 
nous injection of 10 mCi (370 MBq) of FDG. In our later 
experience, mission images were acquired beginning 60 
minutes after FDG injection on the basis of studies using 
dynamic PET imaging that determined the best scanning 
protocol to discriminate benign from malignant pulmo- 
nary lesions, s FDG was synthesized in our laboratory by 
means of standard methods. 6 A region of interest (ROI), 
usually measuring more than 1 cm in diameter, was 
selected on the emission images to include the highest 
intensity of FDG activity in the area of the corresponding 
transmission or radiographic abnormalities. The mean 
ROI activity was corrected for radioactive decay, and a 
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Fig. 2. The true-positive (sensitivity) and false-positive (1 - specificity) rates for diagnosis of malignancy 
for several threshold SURs (SUR >1.5, >1.7, ->2.5, >4.0, and >6.0). 
Fig. 3. Chest CT scan from case 1 obtained uring evaluation of malignant lung nodule. Refer to text for 
clinical history and Fig. 4, A for FDG PET study. 
standardized uptake ratio (SUR) was calculated according 
to the following formula: 
SUR = mean ROI activity (mCi [mBq]/ml)/injected dose 
(mCi [MBq])/body weight (kg) 
To'minimize observer bias, the ROI was selected and 
SUR calculated by a nuclear medicine physician (V.J.L.) 
without prior knowledge of the patient's clinical history, 
physical examination, or laboratory studies (including all 
cytology and biopsy reports). 
A histologic diagnosis was obtained in 84 patients from 
transbronchial or percutaneous biopsy (n = 49) and open 
biopsy or resection (n = 35). Three patients underwent 
extended observation (>2 years) alone without change, or 
gradual resolution, of the radiographic abnormality. Thir- 
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Fig. 4. The FDG PET study in case 1 showed hypermetabolism (indicated byyellow; SUit = 7.8) in the 
lung mass and in a left hilar lymph node that was less than 1 cm in size (A). Diagnosis: Stage Hhmg cancer. 
In case 2, the PET study showed normal myocardial FDG uptake and hypometabolism (absence of yellow; 
SUR = 1.5) in the region of the mass (B). Diagnosis: Hematoma. See text for details. 
teen patients without a definitive pathologic diagnosis and 
less than 2 years of follow-up were excluded. 
Sensitivity, specificity, accuracy, and likelihood ratios 
were calculated with the use of standard equations. Com- 
parison of SUR values between groups with benign and 
malignant disease was performed by means of a two-sided, 
unpaired Student's t test. The null hypothesis was rejected 
at the c~ = 0.05 significance level. Themean -+ standard 
deviation are reported. 
Results 
One hundred patients with focal pulmonary le- 
sions that were indeterminate after chest radiogra- 
phy and CT underwent FDG PET imaging. The 
male/female ratio was 3:2, and mean age was 58 _+ 4 
years. Seventy-nine patients had solit'ary pulmonary 
nodules (defined as a focal abnormality -<-4 cm in 
diameter), and 11 had pulmonary masses (>4 cm in 
diameter). Mean diameter of pulmonary nodules 
and masses was 2.2 _+ 0.8 and 5.2 _+ 0.8 cm, 
respectively. Ten patients had ill-defined pulmonary 
infiltrates. Included in this study were 16 patients 
who had previous lung resections for cancer (7 
solitary nodules and 9 ill-defined opacities). 
Eighty-seven patients had histologic onfirmation 
or extended follow-up to exclude malignancy. A 
histologic diagnosis of bronchogenic carcinoma was 
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Fig. 5. Chest magnetic resonance image from case 2 
demonstrating a right lower lobe mass. Refer to text for 
clinical history and Fig. 4, B for FDG PET study. 
made in 59 patients. The mean (___SD*) SUR was 
6.6 _+ 3.1 for this group (Fig. 1). Carcinoma was 
found in 45 of 67 solitary pulmonary nodules (67%), 
with a mean (_+SD) diameter of 2.3 +_ 0.8 cm; 10 of 
11 pulmonary masses (91%) with a mean (+SD) 
diameter of 5.2 + 0.8 cm; and 4 of 9 pulmonary 
infiltrates (44%). The mean (+SD) SURs for ma- 
lignant solitary nodules, masses, and infiltrates were 
5.5 _+ 2.!, 8.7 +_ 3.8, and 5.1 + 2.0 (range 3.4 to 7.4), 
respectively. 
Twenty-eight patients had benign lesions, which 
included granuloma (n = 4), nonspecific inflamma- 
tion (n -- 6), pneumonia (n = 5), rounded atelecta- 
sis (n = 4), active tuberculosis (n = 2), hamartoma 
(n = 2), carcinoid (n = 2), and a fungal nodule, 
desmoid, and focal pulmonary hemorrhage in one 
case each. Mean (_+SD) SUR was 2.0 _+ 1.6 in this 
group (p = 0.0001 versus malignant disease; un- 
paired t test; two-sided) (Fig. 1): Twenty4wo f 67 
solitary pulmonary nodules were benign (33%), with 
mean diameter of 2.0 _+ 0.6 cm and an SUR of 1.7 _+ 
1.1. One of 11 pulmonary masses was benign (9%), 
measuring 4.6 cm in diameter with an SUR of 1.3. 
Five of nine poorly defined opacities (56%) were 
benign with a mean SUR of 2.8 _+ 2.1 (range 0.8 to 
5.5). 
The true-positive rate (sensitivity) and false-pos- 
itive rate (1 - specificity) of FDG PET for the 
diagnosis of malignancy were determined at several 
SUR levels (Fig. 2). The ideal diagnostic test repre- 
*SD = Standard eviation. 
sents the upper left-hand corner of this plot, where 
the true-positive rate is 1.00 and the false-positive 
rate is 0.00. From this curve, an SUR ->2.5 was 
selected as the best cutoff (the point nearest he 
upper left-hand corner) in terms of minimizing 
diagnostic error when prevalence of malignancy 
approximated 50%. An SUR ->2.5 criterion for 
malignancy achieved a sensitivity, specificity, and 
accuracy of 97% (57/59), 82% (23/28), and 92% 
(80/87), respectively. For lesions 3 cm in diameter or 
smaller (n = 47), sensitivity, specificity, and accuracy 
were 100% (31/31), 81% (13/16), and 94% (44/47), 
respectively. 
Illustrative cases 
CASE 1. A 72 year-old woman, with a 24-pack- 
year history of smoking, had a 2 cm nodular opacity 
on CT (Fig. 3). Her medical history was notable only 
for preoperative forced expiratory volume in 1 sec- 
ond of 0.9, New York Heart Association class II 
congestive heart failure, and a 2 cm adenomatous 
colon polyp removed 6 years earlier. FDG PET 
showed increased accumulation i  the lung mass 
(SUR of 7,8) and in a left hilar lymph node that was 
less than 1 cm in size (Fig. 4, A). Thoracotomy with 
wedge resection of the lingula and mediastinal 
lymph node biopsy were performed. Pathologic ex- 
'amination revealed moderately differentiated ade- 
nocarcinoma with metastasis to one hilar lymph 
node. Comment: True-positive FDG PET.  
CASE 2. A 72-year-old man with a significant 
smoking history, chronic obstructive pulmonary dis- 
ease, and cerebrovascular disease (receiving warfa- 
rin sodium) was referred for evaluation of a right 
lower lobe mass on chest film. He underwent chest 
magnetic resonance imaging (Fig. 5). Transthoracic 
needle aspiration biopsy of the mass revealed only 
necrotic debris, without evidence of malignancy. A 
repeat biopsy 2 weeks later again failed to yield a 
specific diagnosis. He was subsequently referred to 
our clinic, where a third biopsy showed atypical 
spindle cells suggestive of malignancy, as well as 
hemosiderin-laden histiocytes consistent with hem- 
orrhage. Apart from normal myocardial FDG up- 
take, PET failed to show increased accumulation i
the region of the mass (SUR of 1.5) (Fig. 4, B). The 
discharge diagnosis was focal pulmonary hemor- 
rhage, and the patient was observed for more than 2 
years. The mass has shown gradual resolution, and 
the patient remains clinically well. Comment: True- 
negative FDG PET. 
CASE 3. A 73-year-old man, with a 90 pack-year 
history of smoking, underwent horacotomy and 
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Fig. 6. Chest CT scan from case 3 showing a right lung lesion and pleural effusion. Refer to text for clinical 
history and Fig. 7, A for FDG PET study. 
wedge resection of a 2.2 cm diameter nodule in the 
right upper lobe at an outside hospital. Pathologic 
examination revealed a poorly differentiated squa- 
mous cell carcinoma with one diseased hilar lymph 
node. He subsequently received adjuvant radiation 
therapy (5500 cGy). Two years later, he was referred 
to our chest clinic with a pneumonia unimproved 
with medicall therapy. Chest CT demonstrated a 
right lung lesion with pleural effusion (Fig. 6); 
bronchoscopic examination revealed only a granu- 
loma in the right upper lobe bronchus. FDG PET of 
the right lung demonstrated increased FDG uptake 
(SUR of 8.7) in the region of the pleura (Fig. 7, A). 
Cytologic study of thoracentesis fluid confirmed the 
diagnosis of recurrent tumor. Comment: True-posi- 
tive FDG PET. 
CASE 4. An 89-year-old woman, with a history of 
colon carcinoma, had an infiltrate in the right mid- 
dle lobe (Fig. 8). Sputum cytologic results were 
negative for malignancy but positive for acid-fast 
bacillus. FDG PET of the right lung demonstrated 
increased FDG uptake (SUR of 5.5) in the region of 
the infiltrate (Fig. 7, B). Three months after treat- 
ment for tuberculosis, only a minimal streaky opac- 
ity remained on the chest radiograph. Comment: 
False-positive FDG PET. 
Discussion 
FDG PET accurately differentiates benign from 
malignant focal pulmonary abnormalities. In this 
study, an SUR ->2.5 identified malignant lesions 
with 97% sensitivity, 82% specificity, and 92% accu- 
racy. Conversely, an SUR <2.5 demonstrated 82% 
sensitivity and 97% specificity for detecting benign 
disease. False-positive diagnoses, that is, benign 
lesions with SURs ->2.5, were occasionally encoun- 
tered in active infections having FDG uptake similar 
to neoplasms (Fig. 7, B). A recent report has 
demonstrated that the rate of accumulation f FDG 
in inflammatory cells may be different from that in 
tumor cells.* Thus technical improvements in emis- 
sion acquisition time may enhance separation be- 
tween benign and malignant lesions and reduce the 
false-positive rate.* Because the relationship be- 
tween the SUR and cancer isk is not dichotomous 
but rather continuously distributed, the SUR may be 
interpreted as a likelihood ratio, or odds, that at a 
given level of SUR, a certain likelihood of malig- 
nancy exists (Table I). For example, from Table I, a 
lesion with an SUR ->6.0 has a greater than fifteen- 
fold likelihood of being malignant han benign; 
alternatively, a lesion with an SUR <1.5 is always 
benign. FDG PET provides a quantitative estimate 
of relative cancer isk for any pulmonary lesion and 
guides appropriate therapy. 
In the management of indeterminate focal pulmo- 
nary lesions, FDG PET offers distinct advantages 
over transthoracic needle aspiration biopsy and fi- 
beroptic bronchoscopy. The efficacy of bronchos- 
copy to determine the cause of focal lung lesions is 
*Lowe VJ, DeLong DM, Hoffman JM, Coleman RE. Optimum 
scanning protocol for FDG PET evaluation f focal pulmo- 
nary abnormalities. Unpublished data. 
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Fig. 7. The FDG PET study in case 3 showed hypermetabolism (indicated by yellow; SUR = 8.7) in the 
region of the pleura (A). Diagnosis: Recurrent lung cancer. The PET study in case 4 showed hypermetab- 
olism (SUR = 55) (B). Diagnosis: Active tuberculosis. See text for details. 
low. Depending on lesion size and:location, fiberop- 
tic bronchoscopy with biopsy has a. sensitivity of 25% 
to 78% for solitary malignant nodules. 7-9 In partic- 
ular, for malignant lesions measuring 3 to 4 cm in 
diameter, Wallace and Deutsch 9 reported that bron- 
choscopy had a sensitivity of only 56%, which dropped 
to 25% for lesions less than 2 cm in diameter. In 
contrast, the overall 97% sensitivity of FDG PET for 
detecting malignant lesions rose to 100% when limited 
to lesions smaller than 3 cm in diameter. For benign 
disease; bronchoscopy with brushings and transbron- 
chial/Nopsy established a specific diagnosis in only 
12.5% of nodules later proved benign. 7 As the primary 
role of biopsy is to verify benign disease and thereby 
avoid a nontherapeutic thoracotomy, bronchoscopy 
offers little to the overall management of indetermi- 
nate focal pulmonary abnormalities. 
Transthoracic needle aspiration biopsy is highly 
accurate in the diagnosis of bronchogenic arci- 
noma and metastatic disease, with several series 
reporting greater than 95% sensitivity. 1~ How- 
ever, for specific benign disease, such as granu- 
loma and hamartoma, sensitivity drops to 40% to 
50%, with studies ranging from 12% to 69%. 12' 13 
Although higher sensitivity rates are reported in 
studies that combined specific and nonspecific 
benign diagnoses, few would equate a nonspecific 
nonmalignant biopsy with confirmed benign dis- 
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Table I. Likelihood ratios for five levels of SUR 
computed from FDG PET 
Lung cancer 
Likelihood 
Present Absent ratio 
SUR 
->6.0 34 1 16.136 
4.0-5.9 13 2 3.085 
2.5-3.9 10 3 1.582 
1.5-2.49 2 10 0.095 
<1.5 0 12 0.000 
59 28 
ease in view of the potential sampling error. 14 
Thus transthoracic needle aspiration biopsy and 
FDG PET have comparable sensitivities for the 
diagnosis of malignancy, but PET may be pre- 
ferred for the diagnosis of benignancy. Further- 
more, transthoracic needle aspiration biopsy has 
several disadvantages, including (1) a small but 
definite risk of complications, including a 5% to 
10% risk of symptomatic pneumothorax and a 1% 
to 10% risk of minor hemoptysisl4; (2) a delay in 
the diagnosis of benign disease while awaiting the 
results of permanent sections, special stains, or 
cultures; and (3) its relatively high cost (Table II). 
In contrast, FDG PET has no known morbidity 
(apart from that attributable to modest radiation 
exposure), confers a rapid diagnosis, and costs signif- 
icantly less than transthoracic needle aspiration biopsy 
(Table II). Thus, by demonstrating superior sensitivity 
in the diagnosis of benign disease, combined with 
immediate r sults, lower morbidity, and less cost, FDG 
PET may be preferable to transthoracic needle aspi- 
ration biopsy as the procedure of choice in: selected 
patients with focal pulmonary abnormalities. 
This study validates the use of FDG PET for the 
evaluation of solitary pulmonary nodules. To" min- 
imize diagnostic bias, we interpreted:the FDG 
PET images without benefit of clinical material 
(except chest films and CT scans). Although pre- 
cision was not directly addressed in this study, 
objective selection.of the ROI in the area of 
radiographic abnormality greatly minimizes in- 
traobserver error. The potential for interobserver 
variability, howeVer, is of concern because the 
level of concordance between mean ROI mea- 
surements made by different physicians in the 
same patient was not determined. At the 1994 
Annual Meeting of The Society of Thoracic Sur- 
geons, Gupta and associates reported their expe- 
rience with FDG PET for the diagnosis of lung 
Fig. 8. Chest radiograph from case 4 demonstrates a 
right middle lobe infiltrate. Refer to text for clinical 
history and Fig. 7, B for FDG PET study. 
tumors~ In their series of 47 patients, a sensitivity 
of 94% and a specificity of 80% were achieved, 
which was remarkably similar to our experience. 
Although the possibility of interobserver error 
cannot be excluded, good results with FDG PET 
in lung cancer can be reproduced at other medical 
centers; 
To assess the economic impact of FDG PET on 
the diagnosis and management of benign and 
malignant focal pulmonary lesions, we performed 
a cost analysis using two alternative strategies: (1) 
immediate thoracotomy and (2) FDG PET. The 
PET strategy was further subdivided into two 
arms on the basis of the SUR result; SUR ->2.5 
led to thoracotomy and SUR <2.5 warranted 
observation with periodic chest films to assess the 
nodute's rate of growth. To simplify the model, we 
made several conditions and assumptions: (1) all 
lesions were indeterminate, by chest radiography 
and CT, solitary pulmonary nodules less than 3 cm 
in diameter; (2) the pretest probability of malig- 
nancy was 50%; (3) the sensitivity and specificity 
of FDG PET for diagnosis of malignant disease 
were 97% and 82%, respectively; (4) the compli- 
cation rate for thoracotomy was zero; and (5) the 
total hospital stay for thoracotomy was 5 days--that 
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Table II. Hospital charges for four diagnostic procedures used in the evaluation of focal pulmonary 
abnormalities 
Hospital charges 
Transthoracic Transbronchial Open lung 
Category FDG PET needle biopsy biopsy biopsy* 
Hospital $1,081 $ 400 $ 6,261 
Laboratory $ 94 $1,105 $ 1,248 
Pathology department $ 130 $ 947 $ 498 
Radiology department $1,806 $ 602 $ 53 $ 587 
Pharmacy ,, $ 1,030 
M.D. professional fees $ 7761 $1,5021, 3 $1,477l-3 $ 5,3001. 3-5 
Supplies (surgical) $ 81 $ 962 
Respiratory therapy $ 96 
Total $2,582 $3,490 $3,982 $15,982 
Hospital charges (in U.S. dollars) are averages of five patients reated in1993: lradiologist; 2medicine/pulmonologist; 3pathologist; 4anesthesiologist; 5thoracic 
surgeon. 
*Based on a 5-day hospitalization. 
Table I I I .  Cost analysis of two alternative strategies 
for the evaluation of focal pulmonary abnormalities 
in 100 patients 
II. FDG PET 
I. Immediate 
thoracotomy A. SUR >-2.5 B. SUR <2.5 
FDG PET 59 x $2,582 41 'x $2,582 
Open lung 100 x $15,982 59 • $15,982 
biopsy 
Subtotal $1,095,276 $ 105,862 
Total A $1,598,200 $1,201,138 
A -- $397,062 ( 4.8%)--difference between strategy II and I. 
is, patients were discharged on the fourth postopera- 
tive day. The hospital charges and cost analysis for  a 
group of 100 patients are shown in Tables I I  and IlL 
The strategy using FDG PET resulted in 41 fewer 
nontherapeutic operations and reduced overall costs 
by about 25% (Table III). This is a conservative 
estimate, however, that excludes the added cost of a 
longer hospitalization; perioperative complications 
that prolong the length of hospital stay, require inten- 
sive care unit management, or result in long-term 
disability or death; the discomfort and lost wages 
incurred after nontherapeutic thoracotomy; and the 
expense of transbronchial biopsy, transthoracic needle 
aspiration biopsy, or other procedures that might 
otherwise have been used. In our model, one malig- 
nant lesion was not detected on PET and its resection 
was delayed. Options to reduce the false-negative rate 
may include lowering the SUR criterion for malig- 
nancy or repeating the FDG PET at a later date, By 
reducing the number of patients in whom benign 
disease is found during an operation, PET increases 
the diagnostic yield with thoracotomy. By lowering 
overall expenditures for hospitalization and other di- 
agnostic procedures, FDG PET may significantly re- 
duce health care costs.* 
FDG PET was useful in detecting tumor recur- 
rence in patients after lung resection or radiation 
therapy. Of 16 patients who underwent PET after 
treatment for lung cancer, six had histologic evi- 
dence of recurrent umor detected by FDG PET. 
Sites of recurrence included the mediastinum (n = 
3), ipsilateral ung (n = 2), pleura and chest wall 
(n = 2), liver (n = 1), and adrenal gland (n = 1). 
Three patients had two separate sites of recurrence. 
In 10 of 16 patients without recurrence documented 
by reoperation (n = 6) or extended observation (n = 
4), all SURs  were <2.5. The most common benign 
pathologic diagnoses were tissue necrosis and 
fibrosis. Because those part icular benign lesions 
that tended to produce false-positive results on 
PET  (i.e., active tuberculosis or infection) were 
not encountered in this clinical setting, the spec- 
*The effectiveness of video-assisted thoracoscopic surgery 
(VATS) lobectomy over accepted operative techniques has 
not been documented in randomized trials. Thus, in the 
management of indeterminate solitary pulmonary nodules, 
the only accepted role for VATS is as a diagnostic tool. We 
believe, like others (Ann Thorac Surg 1993;56:825-32), that all 
positive thoracoscopic biopsies hould be followed by thora- 
cotomy unless the patient is enlisted in a clinical research 
protocol. Using the same conditions and assumptions enu- 
merated above, the VATS strategy (about $12,180 per proce- 
dure) applied to 100 patients with focal pulmonary abnormal- 
ities would cost over $2,000,000 [(100 • $12,180) + (50 • 
$15,982) = $2,017,100], or nearly $800,000 more than the 
FDG PET arm. 
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ificity of PET was 100%. Currently, PET is rou- 
tinely used to assess uspicious lesions in patients 
with treated lung cancer, so that the need for 
invasive biopsy is avoided. 
Although FDG PET is highly accurate for detect- 
ing pulmonary malignant umors, its ultimate role 
remains undefined. Before widespread application 
of PET can be advocated, studies must first establish 
its cost-effectiveness. The financial impact of FDG 
PET for indeterminate solitary pulmonary nodules 
is currently being investigated in a prospective, 
multicenter clinical trial. Meanwhile, continuing 
studies will focus on improving the diagnostic accu- 
racy of currently used semiquantitative tumor up- 
take indices, evaluating the accuracy of FDG PET in 
smaller lesions (<1 cm diameter), and studying the 
relationship between FDG activity and tumor 
growth rate and clinical outcome. 
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Discussion 
Dr. Robert J. McKenna, Jr. (Los Angeles, Calif.). This 
new technology looks very exciting. Rather than being the 
gallium scan of the 1990s, it probably will play an impor- 
tant, role in the diagnosis and staging of lung cancer. I have 
a few questions regarding the PET scan evaluation of the 
primary tumor and metastatic sites, and I also want to 
make a comment on your cost analysis. 
You categorized the primary tumors as benign versus 
cancer and included in the benign category both inflam- 
matory'and benign tumors. What was the sensitiVity for 
benign tumors versus malignant tumors? Do you know the 
sensitivity of PET scan for different cell types of lung 
cancer and primary versus metastatic tumors? 
Dr. Duhaylongsod. We had 28 benign lesions in the 
study, only one of which was a benign tumor and it was a 
chondromatous hamartoma. It gave an SUR value of 6.0, 
so by our criteria it was a false-positive diagnosis. We 
cannot comment any further because of the small sample 
size. 
Dr. McKenna. How small a tumor volume can the PET 
scan detect? 
Dr. Duhaylongsod. The resolution of current PET 
technology is 5 mm; however, one of our false-negative 
diagnoses was a tumor that was approximately 4 mm 
located in a pleural rind in a patient who had had 
resection. The size is a consideration, and it is an area of 
active research. 
Dr. McKenna. Were there other patients who had 
nodal metastases from their primary tumor? If so, do you 
have a sense yet of how good a job this can do in staging 
the nodal metastases? 
Dr. Duhaylongsod. Although this preliminary study was 
primarily designed to test benign versus malignant, we 
noted many patients having mediastinal involvement as 
well as involvement in the adrenal gland and involvement 
in the liver. The best way to study that would be in a 
prospective fashion. Since the termination of this study we 
are prospectively enrolling patients to do correlative map- 
ping studies of the PET scans versus operative findings. 
Dr., MeKenna. I also want to make a quick comment 
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about the cost of the open lung biopsy. Your numbers 
seem a bit high. For example, last week I did a lobectomy 
on a patient from Hong Kong. My hospital wanted cash up 
front and accepted $9,000 for a right upper lobectomy. 
The patient was home in 3 days. 
Dr. Duhaylongsod. To use the automobile analogy, if 
you are willing to pay cash, the price falls, but this was a 
very simple model. One assumption was that all patients 
undergoing thoracotomies had no complications. A sec- 
ond assumption was that the length of stay was 5 days. 
Obviously there are going to be variations. 
Dr. Donald Hopkins (Sacramento, Calif.). In my prac- 
tice, the PET scan has been used in the management of 75 
patients over the past 18 months. It has been a fascinating 
experience. 
It has been helpful in three areas. The first area is in the 
evaluation and management of pulmonary nodules, 
masses, and indeterminant densities. Our experience 
closely parallels the Duke results. We also use the SUR 
value of 2.5 as the best number to separate benign from 
malignant densities. I would like to emphasize that a 
negative on a PET scan (that is, a zero SUR), even for 
nodules of I cm or less, has indicated to us that the density 
in question is not malignant. It is very helpful to have 
negative information on a solitary nodule or when multi- 
ple nodules are present either in one or both of the lungs. 
Second, the PET scan is an accurate way of demonstrat- 
ing the presence or absence of recurrent malignancy in a 
suspicious clinical setting. 
Third, we have been encouraged at how helpful the 
PET scan technique is in staging bronchogenic carcinoma. 
Our numbers are small, but PET has been more accurate 
than CT scanning in predicting mediastinal N2disease. 
Our experience with 37 patients with newly diagnosed 
lung cancer has shown positive and negative predictive 
values for the mediastinal and hilar nodes of 90% and 
93%, respectively, whereas our CT scan values were only 
50% and 78%, respectively. These were all confirmed by 
mediastinal lymphadenectomy at the time of thoracotomy 
or by mediastinoscopy biopsy. In identifying M1, stage IV 
disease, an "up,front" PET scan has demonstrated unsus- 
pected metastatic lesions at a variety of unusual locations. 
Those pesky 2 to 3 cm adrenal gland nodules een on the 
CT scan can be evaluated accurately with the PET scan. 
Isotope bone scan and osseous x-ray lesions are easily 
evaluated by PET scan. The same is true for hepatic 
lesions. Though valuable information about he brain can 
be obtained with the PET scan, the magnetic resonance 
image with gadolinium still remains the most sensitive way 
to demonstrate intracranial metastatic lesions. 
Your fiscal analysis is pertinent and is the kind of 
information that should be presented to Medicare and 
insurance carriers. PET scanning is an expensive technol- 
ogy and reimbursement is needed. The bottom line, I 
believe, is that PET Scanning when used appropriately, 
and the term appropriate has to be worked out with 
continued experience, will not only prove to be cost- 
effective, but more importantly will contribute to im- 
proved patient care. I would urge all the members of our 
association to become interested and informed and to 
take an active part in the clinical use of the PET scan. 
Dr. Ahmed El Gamel (Manchester, United Kingdom). I
have one question. Because you do not have 100% 
accuracy or 100% specificity, how frequently are you going 
to follow up the patients? You have to compare the 
follow-up cost of this procedure with that of other proce- 
dures. 
Dr. Duhaylongsod. Because our specificity is not 100%, 
patients with an SUR <2.5 obviously need to be followed 
UP. We recommend repeating the PET scan over a 2 to 3 
month period, although one may choose transbronchial 
biopsy or needle aspiration biopsy instead after the FDG 
PET scan. One thing that has been interesting in the 
evolution of this technology is that initially all patients 
who were referred to our institution had transbronchial 
biopsies or needle aspiration biopsies before they arrived. 
However, since the closure of this study, the practice 
patterns of our pulmonologists have changed. Now, all 
they order are FDG PET studies, and patients are going 
directly to the operating room with the result of a PET 
scan. I think that this is a very interesting change in 
behavior. 
